TY - JOUR
T1 - The nested open reading frame in the Epstein-Barr virus nuclear antigen-1 mRNA encodes a protein capable of inhibiting antigen presentation in cis
AU - Ossevoort, Martine
AU - Zaldumbide, Arnaud
AU - te Velthuis, Aartjan J.W.
AU - Melchers, Mark
AU - Ressing, Maaike E.
AU - Wiertz, Emmanuel J.H.J.
AU - Hoeben, Rob C.
N1 - Funding Information:
We thank Danielle Horst, Danijela Koppers-Lalic, Ellen I.H. van der Voort, René E.M. Toes, Steve J. Cramer for their help in generation of β-galactosidase-specific CTL and IFNγ quantification, plasmid construction, and stimulating discussions. Daphne van Leeuwen and Jan-Wouter Drijfhout are acknowledged for sharing their expertise in antibody production. This work was supported by the Dutch Cancer Society (UL 2005-3259), the M.W. Beijerinck Virology Fund of the Royal Academy of Arts and Sciences (to M.E.R.), and the Netherlands Organisation for Scientific Research (Vidi 917.76.330 to M.E.R.).
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2007/7
Y1 - 2007/7
N2 - Herpesviruses employ many mechanisms to evade the immune response, allowing them to persist life-long in their hosts. The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) and, more recently, the latency-associated nuclear antigen 1 (LANA-1) of the Kaposi Sarcoma Herpesvirus have been shown to function as in cis-acting inhibitors of antigen presentation. In both proteins, long simple repeat elements are responsible for the inhibition, but the sequences of these repeats are strongly dissimilar. Intriguingly, EBNA-1 mRNA contains a large nested open reading frame that codes for a 40.7 kDa strongly acidic protein, in addition to the full-length EBNA-1. This protein, here called pGZr, has a 230 amino-acids long glycine, glutamine, and glutamic acid-rich repeat ('GZ' repeat), highly similar (65% amino-acid identity) to the acidic repeat of LANA-1. To evaluate if pGZr, like EBNA-1 and LANA-1, can inhibit antigen presentation in cis, we fused the nested ORF with the E. coli-derived LacZ gene encoding β-galactosidase. Whereas cells producing the unmodified β-galactosidase readily present the H-2Ld-restricted CTL epitope TPHPARIGL, which resides in the C-terminal region of β-galactosidase, cells producing the pGZr-β-galactosidase fusion protein do not. Also shorter fragments of the repeat can inhibit peptide presentation. Even though the physiological function of pGZr remains to be elucidated, the GZ-repeat protein may be valuable as inhibitor of presentation of antigenic peptides derived from transgenes in gene therapy.
AB - Herpesviruses employ many mechanisms to evade the immune response, allowing them to persist life-long in their hosts. The Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA-1) and, more recently, the latency-associated nuclear antigen 1 (LANA-1) of the Kaposi Sarcoma Herpesvirus have been shown to function as in cis-acting inhibitors of antigen presentation. In both proteins, long simple repeat elements are responsible for the inhibition, but the sequences of these repeats are strongly dissimilar. Intriguingly, EBNA-1 mRNA contains a large nested open reading frame that codes for a 40.7 kDa strongly acidic protein, in addition to the full-length EBNA-1. This protein, here called pGZr, has a 230 amino-acids long glycine, glutamine, and glutamic acid-rich repeat ('GZ' repeat), highly similar (65% amino-acid identity) to the acidic repeat of LANA-1. To evaluate if pGZr, like EBNA-1 and LANA-1, can inhibit antigen presentation in cis, we fused the nested ORF with the E. coli-derived LacZ gene encoding β-galactosidase. Whereas cells producing the unmodified β-galactosidase readily present the H-2Ld-restricted CTL epitope TPHPARIGL, which resides in the C-terminal region of β-galactosidase, cells producing the pGZr-β-galactosidase fusion protein do not. Also shorter fragments of the repeat can inhibit peptide presentation. Even though the physiological function of pGZr remains to be elucidated, the GZ-repeat protein may be valuable as inhibitor of presentation of antigenic peptides derived from transgenes in gene therapy.
KW - Antigen
KW - Epstein-Barr virus
KW - Fusion protein
KW - Immune evasion
KW - Proteasome
UR - http://www.scopus.com/inward/record.url?scp=34248582393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248582393&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2007.03.005
DO - 10.1016/j.molimm.2007.03.005
M3 - Article
C2 - 17449101
AN - SCOPUS:34248582393
SN - 0161-5890
VL - 44
SP - 3588
EP - 3596
JO - Immunochemistry
JF - Immunochemistry
IS - 14
ER -